48
Participants
Start Date
December 1, 2022
Primary Completion Date
October 31, 2024
Study Completion Date
December 31, 2029
Serplulimab, Albumin paclitaxel, carboplatin AUC=5, neoadjuvant therapy
Serplulimab 4.5mg/kg, IV, Day 1; Albumin paclitaxel 260mg/m2, Day 1; carboplatin AUC=5, Day 1; Preoperative neoadjuvant therapy for 3 cycles, one cycle every 21 days.
Esophagectomy
"Prior to each surgical procedure, the department engaged in comprehensive discussions and deliberations to ascertain and establish the most suitable course of action. Minimally invasive Ivor-Lewis (intrathoracic anastomosis) or McKeown (neck anastomosis) esophagectomy, including two field extensive lymphadenectomies, was performed according to the tumor location. The resection length should be at least 5cm from the tumor origin according to prechemotherapy by endoscopy.~The surgeries will be performed by surgeons with rich experience. Minimally invasive esophagectomy, can be performed using the da Vinci surgical robot, thoracoscope, or laparoscope, or by using an open approach, as judged appropriate by the surgeon."
sample
"Blood, Tumour will be Collected from participant. Fate of sample is Destruction after use.~5 ml of peripheral blood was collected the day before each of the immunotherapy sessions and after surgery.~Tumour sample will be collected before neoadjuvant therapy and after surgery."
2nd Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou
Second Affiliated Hospital, School of Medicine, Zhejiang University
OTHER